Lavin Consulting, LLC   Report issue

For profit Phase 2
Founded: Framingham MA United States (2012)

Organization Overview

First Clinical Trial
2020
NCT04311697
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Lavin Consulting, LLC

Active Ingredients

Drugs in Phase 2 Trials (1)

aviptadil (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Lung Injury (Phase 2)

Coronavirus Infections (Phase 2)

Lung Injury (Phase 2)

Respiratory Distress Syndrome (Phase 2)

Respiratory Distress Syndrome, Newborn (Phase 2)

Severe Acute Respiratory Syndrome (Phase 2)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1